{"id":"quadrivalent-recombinant-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-15","effect":"Injection site erythema"},{"rate":"5-10","effect":"Injection site swelling"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The quadrivalent recombinant influenza vaccine contains recombinant hemagglutinin proteins from four influenza virus strains (two A strains and two B strains) produced using recombinant DNA technology in insect cells. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of strain-specific antibodies and T-cell immunity that protect against infection with matching influenza viruses.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:25.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in adults 18 years of age and older"}]},"trialDetails":[{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT04451954","phase":"PHASE1","title":"Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-07-02","conditions":"Influenza Immunisation, Healthy Volunteers","enrollment":210},{"nctId":"NCT05829356","phase":"PHASE1","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-04-12","conditions":"Influenza Immunization","enrollment":159},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT05513053","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-27","conditions":"Influenza Immunization","enrollment":1308},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT04144179","phase":"PHASE1","title":"Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-06","conditions":"Influenza","enrollment":150},{"nctId":"NCT06361875","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":"Influenza Immunization","enrollment":910},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT05514002","phase":"PHASE4","title":"Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years","status":"TERMINATED","sponsor":"Fatimah Dawood","startDate":"2022-09-13","conditions":"Influenza, Human","enrollment":3988},{"nctId":"NCT05650554","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-12-12","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05553301","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-03","conditions":"Influenza Immunization","enrollment":560},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT03722589","phase":"PHASE4","title":"Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-09-12","conditions":"Influenza","enrollment":944},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT05409612","phase":"PHASE3","title":"Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-07","conditions":"Morbid Obesity, Severe Obesity","enrollment":206},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT04576377","phase":"PHASE4","title":"Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-10-05","conditions":"Influenza, Human","enrollment":977},{"nctId":"NCT03734237","phase":"PHASE4","title":"A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD","status":"UNKNOWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2018-11-06","conditions":"Influenza, Influenza-like Illness, Influenza Vaccines","enrollment":15449},{"nctId":"NCT04523324","phase":"PHASE4","title":"Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-31","conditions":"Influenza","enrollment":577},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT06118151","phase":"PHASE1","title":"Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-04-11","conditions":"Influenza, Influenza Immunization","enrollment":388},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT03965195","phase":"PHASE4","title":"Recombinant Influenza Vaccination in U.S. Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2019-07-20","conditions":"Influenza, Influenza -Like Illness, Influenza, Human","enrollment":1989},{"nctId":"NCT03969641","phase":"PHASE4","title":"Safety of RIV4 Versus IIV4 in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-09-05","conditions":"Safety, Adverse Event Following Immunisation, Birth Outcomes","enrollment":384},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT04192500","phase":"PHASE2","title":"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","status":"COMPLETED","sponsor":"Osivax","startDate":"2019-12-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT03460743","phase":"PHASE3","title":"Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2018-03-22","conditions":"Influenza, Human","enrollment":1556},{"nctId":"NCT02285998","phase":"PHASE3","title":"Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":9003},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":"Human Influenza","enrollment":254648},{"nctId":"NCT02290509","phase":"PHASE3","title":"Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1350},{"nctId":"NCT02307851","phase":"PHASE2","title":"Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2014-11","conditions":"Influenza","enrollment":400},{"nctId":"NCT01959945","phase":"PHASE3","title":"Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-11","conditions":"Influenza","enrollment":219},{"nctId":"NCT01096134","phase":"NA","title":"Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2011-01","conditions":"Cervical Cancer","enrollment":8000},{"nctId":"NCT02434276","phase":"PHASE2","title":"Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2015-05","conditions":"Influenza","enrollment":450},{"nctId":"NCT02247362","phase":"PHASE1, PHASE2","title":"Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2014-11","conditions":"Influenza","enrollment":200},{"nctId":"NCT02015494","phase":"PHASE1","title":"Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2014-03","conditions":"Influenza","enrollment":316},{"nctId":"NCT01561768","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-03","conditions":"Influenza","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flublok Quadrivalent®","Flublok Quadrivalent","RIV4"],"phase":"marketed","status":"active","brandName":"Quadrivalent Recombinant Influenza Vaccine","genericName":"Quadrivalent Recombinant Influenza Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection. Used for Prevention of seasonal influenza in adults 18 years of age and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}